An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-B--1a and hydroxychloroquine in hospitalized patients with COVID-19

This is a publication. If there is no link to the publication on this page, you can try the pre-formated search via the search engines listed on this page.

Authors: Florence Ader 1, Nathan Peiffer-Smadja 2, Julien Poissy 3, Maude Bouscambert-Duchamp 4, Drifa Belhadi 5, Alpha Diallo 6, Christelle Delmas 7, Juliette Saillard 7, Aline Dechanet 8, Noémie Mercier 6, Axelle Dupont 9, Toni Alfaiate 9, François-Xavier Lescure 10, François Raffi 11, François Goehringer 12, Antoine Kimmoun 13, Stéphane Jaureguiberry 14, Jean Reign

Journal title: Clinical Microbiology and Infection

Journal publisher: Elsevier

Published year: 2021

DOI identifier: 10.1016/j.cmi.2021;05.020